d-Dimer elevation and adverse outcomes

Rim Halaby; Christopher J. Popma; Ander Cohen; Gerald Chi; Marcelo Rodrigues Zacarkim; Gonzalo Romero; Samuel Z. Goldhaber; Russell Hull; Adrian Hernandez; Robert Mentz; Robert Harrington; Gregory Lip; Frank Peacock; James Welker; Ignacio Martin-loeches; Yazan Daaboul; Serge Korjian; C. Michael Gibson

doi:10.1007/s11239-014-1101-6

d-Dimer elevation and adverse outcomes

Rim Halaby, Christopher J. Popma, Ander Cohen, Gerald Chi, Marcelo Rodrigues Zacarkim, Gonzalo Romero, Samuel Z. Goldhaber, Russell Hull, Adrian Hernandez, Robert Mentz, Robert Harrington, Gregory Lip, Frank Peacock, James Welker, Ignacio Martin-loeches, Yazan Daaboul, Serge Korjian, C. Michael Gibson

Cardiovascular Sciences

Research output: Contribution to journal › Article › peer-review

30 Citations (Scopus)

908 Downloads (Pure)

Abstract

d-Dimer is a biomarker of fibrin formation and degradation. While a d-dimer within normal limits is used to rule out the diagnosis of deep venous thrombosis and pulmonary embolism among patients with a low clinical probability of venous thromboembolism (VTE), the prognostic association of an elevated d-dimer with adverse outcomes has received far less emphasis. An elevated d-dimer is independently associated with an increased risk for incident VTE, recurrent VTE, and mortality. An elevated d-dimer is an independent correlate of increased mortality and subsequent VTE across a broad variety of disease states. Therefore, medically ill subjects in whom the d-dimer is elevated constitute a high risk subgroup in which the prospective evaluation of the efficacy and safety of antithrombotic therapy is warranted.

Original language	English
Journal	Journal of thrombosis and thrombolysis
DOIs	https://doi.org/10.1007/s11239-014-1101-6
Publication status	Published - 9 Jul 2014

Access to Document

10.1007/s11239-014-1101-6

Lip_D_Dimer_elevation_adverse_outcomes_Journal_Thrombosis_Thrombolysis
Eligibility for repository : checked 24/07/2014
Final published version, 188 KBLicence: Creative Commons: Attribution (CC BY)

http://link.springer.com/10.1007/s11239-014-1101-6

Cite this

Halaby, R., Popma, C. J., Cohen, A., Chi, G., Zacarkim, M. R., Romero, G., Goldhaber, S. Z., Hull, R., Hernandez, A., Mentz, R., Harrington, R., Lip, G., Peacock, F., Welker, J., Martin-loeches, I., Daaboul, Y., Korjian, S., & Gibson, C. M. (2014). d-Dimer elevation and adverse outcomes. Journal of thrombosis and thrombolysis. https://doi.org/10.1007/s11239-014-1101-6

@article{752f9cc0d92346f393e852b2b6ea37cf,

title = "d-Dimer elevation and adverse outcomes",

abstract = "d-Dimer is a biomarker of fibrin formation and degradation. While a d-dimer within normal limits is used to rule out the diagnosis of deep venous thrombosis and pulmonary embolism among patients with a low clinical probability of venous thromboembolism (VTE), the prognostic association of an elevated d-dimer with adverse outcomes has received far less emphasis. An elevated d-dimer is independently associated with an increased risk for incident VTE, recurrent VTE, and mortality. An elevated d-dimer is an independent correlate of increased mortality and subsequent VTE across a broad variety of disease states. Therefore, medically ill subjects in whom the d-dimer is elevated constitute a high risk subgroup in which the prospective evaluation of the efficacy and safety of antithrombotic therapy is warranted.",

author = "Rim Halaby and Popma, {Christopher J.} and Ander Cohen and Gerald Chi and Zacarkim, {Marcelo Rodrigues} and Gonzalo Romero and Goldhaber, {Samuel Z.} and Russell Hull and Adrian Hernandez and Robert Mentz and Robert Harrington and Gregory Lip and Frank Peacock and James Welker and Ignacio Martin-loeches and Yazan Daaboul and Serge Korjian and Gibson, {C. Michael}",

year = "2014",

month = jul,

day = "9",

doi = "10.1007/s11239-014-1101-6",

language = "English",

journal = "Journal of thrombosis and thrombolysis",

issn = "0929-5305",

publisher = "Springer",

}

TY - JOUR

T1 - d-Dimer elevation and adverse outcomes

AU - Halaby, Rim

AU - Popma, Christopher J.

AU - Cohen, Ander

AU - Chi, Gerald

AU - Zacarkim, Marcelo Rodrigues

AU - Romero, Gonzalo

AU - Goldhaber, Samuel Z.

AU - Hull, Russell

AU - Hernandez, Adrian

AU - Mentz, Robert

AU - Harrington, Robert

AU - Lip, Gregory

AU - Peacock, Frank

AU - Welker, James

AU - Martin-loeches, Ignacio

AU - Daaboul, Yazan

AU - Korjian, Serge

AU - Gibson, C. Michael

PY - 2014/7/9

Y1 - 2014/7/9

N2 - d-Dimer is a biomarker of fibrin formation and degradation. While a d-dimer within normal limits is used to rule out the diagnosis of deep venous thrombosis and pulmonary embolism among patients with a low clinical probability of venous thromboembolism (VTE), the prognostic association of an elevated d-dimer with adverse outcomes has received far less emphasis. An elevated d-dimer is independently associated with an increased risk for incident VTE, recurrent VTE, and mortality. An elevated d-dimer is an independent correlate of increased mortality and subsequent VTE across a broad variety of disease states. Therefore, medically ill subjects in whom the d-dimer is elevated constitute a high risk subgroup in which the prospective evaluation of the efficacy and safety of antithrombotic therapy is warranted.

AB - d-Dimer is a biomarker of fibrin formation and degradation. While a d-dimer within normal limits is used to rule out the diagnosis of deep venous thrombosis and pulmonary embolism among patients with a low clinical probability of venous thromboembolism (VTE), the prognostic association of an elevated d-dimer with adverse outcomes has received far less emphasis. An elevated d-dimer is independently associated with an increased risk for incident VTE, recurrent VTE, and mortality. An elevated d-dimer is an independent correlate of increased mortality and subsequent VTE across a broad variety of disease states. Therefore, medically ill subjects in whom the d-dimer is elevated constitute a high risk subgroup in which the prospective evaluation of the efficacy and safety of antithrombotic therapy is warranted.

U2 - 10.1007/s11239-014-1101-6

DO - 10.1007/s11239-014-1101-6

M3 - Article

SN - 0929-5305

JO - Journal of thrombosis and thrombolysis

JF - Journal of thrombosis and thrombolysis

ER -

d-Dimer elevation and adverse outcomes

Abstract

Access to Document

Fingerprint

Cite this